27. GLP-1 RA Added to Insulin Results in Durable Weight Loss and Glycemic Control in Type 2 Diabetes Patients: 2 Years Real-Life Follow-up Data (976-P)

The study was aimed to assess the macronutrient intake pattern and its association to glycemic status and drug intake pattern of type 2 diabetes patients. Forty five subjects (25 males and 20 females) aged between 30 and 60 years, diagnosed with diabetes for less than 3 years were enrolled into the study. Based on Oral Anti-Diabetic drugs (OAD) treatment, they were grouped as those on mono-therapy (GpI, n=21) and dual therapy (GpII, n=25). Information about drugs profile, macronutrient intake (3 days diet recall reported as % equivalent of energy) and serum glucose profile were obtained at baseline and a 6th month follow up. Mean CHO, protein and fat intakes were 65.4±4.84, 12.6±1.26 and 22.0±4.7 % of total energy at baseline and remained essentially similar at 6th month. Patients who had controlled glycemic status (HbA1C ≤ 7 %) consumed 63.4±2.70 % CHO which was significantly (P<0.05) lower than those with not-controlled glycemic status (HbA1C >7 %) during both the assessment periods. Also, mean protein intake was higher and fat intake was lower among patients with good glycemic control. Significantly a higher proportion of (P<0.05) patients consuming CHO > 65 % were on dual therapy. A diet with lower carbohydrates and fat but high protein exerted good glycemic control. Number of OADs and their dosages were significantly associated to CHO intakes. Since Indian diets are predominantly carbohydrate rich, it calls for a careful management of diet among Type 2 diabetes patients

Download Full-text

The Mid-Term Effects of Transit Bipartition with Sleeve Gastrectomy on Glycemic Control, Weight Loss, and Nutritional Status in Patients with Type 2 Diabetes Mellitus: a Retrospective Analysis of a 3-Year Follow-up

Obesity Surgery ◽

10.1007/s11695-021-05536-1 ◽

2021 ◽

Author(s):

Akin Calisir ◽

Ilhan Ece ◽

Huseyin Yilmaz ◽

Husnu Alptekin ◽

Fahrettin Acar ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Weight Loss ◽

Type 2 Diabetes Mellitus ◽

Sleeve Gastrectomy ◽

Glycemic Control ◽

Nutritional Status ◽

Transit Bipartition

Download Full-text

SGLT 2 Inhibitors; glycemic control, weight loss and safety profile in patients with type 2 Diabetes, at Medicell Institute (MIDEM)

Pakistan Journal of Medical Sciences ◽

10.12669/pjms.37.1.2701 ◽

2020 ◽

Vol 37 (1) ◽

Author(s):

Erum Sohail Nathani ◽

Tasnim Ahsan ◽

Saima Ghaus ◽

Wasfa Aijaz

Keyword(s):

Type 2 Diabetes ◽

Weight Loss ◽

Glycemic Control ◽

Safety Profile ◽

Original Work ◽

Additional Advantage ◽

Creative Commons ◽

Open Access Article

Background & Objective: Sodium glucose co-transporter-2 inhibitors (SGLT 2 inhibitors) are newer anti-hyperglycemic agents, which improve glycemic control independent of insulin secretion with a low risk of hypoglycemia. This study aimed to assess the efficacy of SGLT 2 inhibitors in terms of glycemic control, weight reduction and safety profile in our patients with type 2 Diabetes (T2D). Methods: This is a prospective analysis, conducted at Medicell Institute of Diabetes, Endocrinology and Metabolism (MIDEM), Karachi Pakistan from January 2018 till July 2019. This study included patients with T2D, who were treated with SGLT 2 inhibitors add on to other anti-diabetic drugs. Baseline and follow up weight, BMI, HbA1c, blood pressure (BP), renal function and side effect profile was assessed. Results: Study included 140 patients; 53% females and 47% males. Mean Age was 55.6 ± 10.3 years. Mean weight at baseline was 81.5 ±16.5 kg. Mean duration of T2D was 10.3 ± 6.75 years, with a mean HbA1C at baseline of 9.1± 1.6%. Follow up data was available for 90 patients at the time of analysis. HbA1C improved considerably to 7.6± 0.9 (P< 0.001) and mean weight reduced to 78.5 ± 16.1 kg (P≤0.003), at first follow-up. Conclusion: Dapagliflozin and Empagliflozin offer a significant additional drug in improving glycemic control with the additional advantage of weight loss and hypoglycemia safety. doi: https://doi.org/10.12669/pjms.37.1.2701 How to cite this:Sohail E, Ahsan T, Ghaus S, Aijaz W. SGLT 2 Inhibitors; glycemic control, weight loss and safety profile in patients with type 2 Diabetes, at Medicell Institute (MIDEM). Pak J Med Sci. 2021;37(1):87-92. doi: https://doi.org/10.12669/pjms.37.1.2701 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download Full-text